| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.16 | 5e-06 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.17 | 8e-06 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-05 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.23 | 2e-05 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-05 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-05 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 5e-05 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-05 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.23 | 6e-05 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | 0.21 | 6e-05 |